Sign in
VBIO Stock Price, Chart, Stats & News
Valion Bio, Inc.
Save
Valion Bio, Inc. (VBIO) does not currently pay a dividend.
9.44M
Market cap
–
Current P/E
–
Forward P/E
VBIO chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -98.22% |
ROE | -82.10% |
D/E | – |
Interest coverage ratio | – |
VBIO valuation
P/E | – |
P/S | – |
P/B | 22.96x |
P/CF | -12.35x |
P/FCF | – |
P/OCF | -12.35x |
PEG | -0.23x |
EV multiple | -1.00x |
About
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence.
Similar securities
Based on sector and market capitalization
Report issue